Results 21 to 30 of about 219,878 (216)

Pneumonitis and multiple pneumonial infections under combined immune‐checkpoint inhibition

JEADV Clinical Practice, 2023
The introduction of immune checkpoint inhibitors and targeted therapies has revolutionized melanoma treatment. The downside are immune‐mediated adverse events which are frequent and require close patient management.
Kristine E. Mayer, Thomas Gan, Jochen Gaa, Tilo Biedermann, Christian Posch   +4 more
doaj   +1 more source

Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma

Journal of Immunology Research, 2020
Cancer cells escape immune recognition by exploiting the programmed cell-death protein 1 (PD-1)/programmed cell-death 1 ligand 1 (PD-L1) immune checkpoint axis.
John Apostolidis, Ayman Sayyed, Mohammed Darweesh, Panayotis Kaloyannidis, Hani Al Hashmi   +4 more
doaj   +1 more source

Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma

BMC Pulmonary Medicine, 2021
Background The role of immunotherapy in cancer is now well-established, and therapeutic options such as checkpoint inhibitors are increasingly being approved in many cancers such as non-small cell lung cancer (NSCLC). Malignant pleural mesothelioma (MPM)
Steven G. Gray
doaj   +1 more source

Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy

Vaccines, 2023
Hepatitis B virus (HBV) infection is the main risk factor for the development of hepatocellular carcinoma (HCC), the most common type of liver cancer, with high incidence and mortality worldwide.
Jin Zhang, Changwei Hu, Xiaoxiao Xie, Linzhi Qi, Chuanzhou Li, Shangze Li   +5 more
doaj   +1 more source

Nephrotoxicity of checkpoint inhibitors; a current challenge [PDF]

Journal of Nephropharmacology
Immune checkpoint inhibitors work by blocking the "checkpoint" mechanism that tumors use to hide from the immune system, therefore also weakening the immune system.
Samaneh Zandifar, Mahshid Imankhan, Padideh Daneii, Ali Azarpey, Leila Alem   +4 more
doaj   +1 more source

Progress of Biomarkers to Predict Response to Immune Checkpoint Inhibitors in Microsatellite Stability Colorectal Cancer

Zhongliu Fangzhi Yanjiu, 2023
The exploration of biomarkers predicting response to immune checkpoint inhibitors in microsatellite stability colorectal cancer can enable more patients to benefit from immunotherapy.
WANG Zhiqiang, DONG Shuai, LI Menglong, LIANG Rui   +3 more
doaj   +1 more source

Tracking the tail

Journal for ImmunoTherapy of Cancer, 2020
Immune-checkpoint inhibitors have deeply changed the therapeutic landscape of advanced non-small cell lung cancer without actionable genomic alterations. Immune-checkpoint inhibitors have become standard front-line therapy, especially among patients with
Alex Friedlaender, Alfredo Addeo, Stephen V Liu   +2 more
doaj   +1 more source

The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy

Frontiers in Oncology, 2022
The emergence of checkpoint inhibitors has created a paradigm shift for the treatment of various malignancies. However, although these therapies are associated with improved survival rates, they also carry the risk of immune-related adverse events (irAEs)
Sebastian Bruera, Maria E. Suarez-Almazor   +1 more
doaj   +1 more source

The Future of Checkpoint Inhibitors in Uveal Melanoma: A Narrative Review

Ophthalmology and Therapy
Introduction Immune checkpoint inhibitors have made tremendous progress over the last decade in the treatment of cutaneous melanoma, but their application in uveal melanoma treatment is less successful, owing in part to the immunological privilege of the
Jinyu Wang, Zehua Li, Hongbo Yin
doaj   +1 more source

Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management

Kidney Medicine, 2021
Immune checkpoint inhibitors are now approved for more than 50 indications, and increasing numbers of patients with advanced cancer are receiving immunotherapy.
Harish Seethapathy, Sandra M. Herrmann, Meghan E. Sise   +2 more
doaj   +1 more source